App-Quantinova.ai

Assessment of treatment adherence in rheumatoid arthritis italian patients using a validated version of the 5-item compliance questionnaire for rheumatology (I-CQR5

F. Ometto - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. analysis from the dcvas study

S Monti - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

N/A

Association between organ damage and health-related quality of life in systemic lupus erythematosus (SLE: a systematic review

E.R. Hammond - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Association of childhood and adulthood adiposity measures with knee cartilage thickness, cartilage volume and bone area in young adults

T. Meng - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Associations between clinical manifestations of behcet’s syndrome and work outcomes: results from a uk cross-sectional analysis

L. Chadwick - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Behcet disease

N/A

Associations of osteoclasts and macrophages in subchondral bone with symptoms in people with knee oa

K. Aso - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

At diagnosis of rheumatoid arthritis, at-risk patients followed in ccp+ clinic showed milder disease activity than conventionally referred patients.

L. Duquenne - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase iib address ii study and its long-term extension

E. Morand - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Prednisone

Audit of influenza and pneumococcal vaccinations in a cohort of rheumatoid arthritis patients on biologics

S. Selvan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Audit of the clinical efficacy and safety of etanercept biosimilar to its reference product in patients with inflammatory arthritis: experience from a district general hospital in the united kingdom

J. Ma - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Etanercept biosimilar

Audit of the management of gout -are we doing it right?

T.J. Khan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Gout

Febuxostat

Autologous hematopoietic stem cell transplantation (HSCT for anti-neutrophil cytoplasmic antibody (ANCA-associated vasculitis (AAV – a ebmt retrospective survey

T. Alexander - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Rituximab

Automated scoring of knee osteoarthritis (OA on routine radiographs identifies disease severity in oa

A. Law - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Axial spondyloarthritis posture assessment using inertial sensors

J.L. Garrido-Castro - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Baricitinib in systemic lupus erythematosus (SLE: results from a phase 2, randomised, double-blind, placebo-controlled study

D.J. Wallace - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Baricitinib

Barriers against testing anti-tnf drug levels and anti-drug antibodies in routine clinical practice

S.P. Gavan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Barriers to remain in work: results from the national rheumatoid arthritis society survey (NRAS

S. Verstappen - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Baseline predictors of response to methotrexate in early rheumatoid arthritis

S. Rizvi - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Big data for treatment effectiveness and safety

L. Tomlinson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

N/A

Bio-similar to bio-originator switchback: not a reliable quality indicator

S.Y. Lee - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Etanercept biosimilar

Filters

45280 Abstracts